Equigerminal · Science & Research
DOC // IP-001 · 2025
Intellectual
Property
Protecting the future of equine biotechnology through proprietary molecular innovations — from viral diagnostics to next-generation antiviral therapeutics targeting the New Equine Virus.
[ ACTIVE PATENT FAMILIES ]
F.01 // Viral Peptides · WO2015094001A1
F.02 // Antiviral Composition · WO2016195522A2
[ 01 / 03 ]
10×
Int. Processes
Active international patent processes across jurisdictions.
[ 02 / 03 ]
01
Bio. Deposit
Certified biological patent deposit under international treaty.
[ 03 / 03 ]
04×
Granted Patents
Formally granted across EU, United Kingdom, and Australia.
Core Patent Families
02 / ACTIVE
Family · 01 of 02
WO2015094001A1
Viral
Peptides
Protects proprietary viral peptide sequences derived from the New Equine Virus (NEV) for diagnostic assay development and peptide-based immunotherapeutics — establishing foundational molecular IP for the entire NEV platform.
Family · 02 of 02
WO2016195522A2
Antiviral
Composition
Protects a novel class of antiviral compounds designed to treat NEV-associated viral infections — constituting a proprietary therapeutic platform with potential applicability across equine virology and adjacent indications.
Granted
Portfolio
Portfolio
04 GRANTED
03 JURISDICTIONS
03 JURISDICTIONS
#
Family
Grant Reference
Territory
01
Viral Peptides
EP3083659B
EU//European Patent Office
02
Viral Peptides
GB2526222B
GB//United Kingdom
03
Antiviral Composition
GB2544439B
GB//United Kingdom
04
Antiviral Composition
AU2017271995B
AU//Australia
Additional IP
Biological
Patent Deposit
Beyond standard patent filings, Equigerminal holds 1 certified biological patent deposit — formally depositing biological material under international treaty standards to guarantee legal reproducibility and long-term scientific authenticity of the NEV platform.